Treating children with HIV infection: What we can do, we should do

Clinical Infectious Diseases

Volumn 44, Issue 4, 2007, Pages 605-606

  Oleske, James M ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; DRUG INDICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MORBIDITY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; THAILAND; THERAPY DELAY;

ADOLESCENT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33846926558     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510495     Document Type: Note

References (7)

1. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-604 (in this issue).
2. Gortmaker SL, Hughes M, Cervia J, et al., for the Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522-8.
3. Brogly S, Williams P, Seage GR III, Oleske JM, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV in the United States: from clinical trials to clinical practice. PACTG 219C Team. JAMA 2005; 293:2213-20.
4. Soh CH, Oleske JM, Brady MT, et al. Long-term effects of combination therapy including protease inhibitors on CD4 T cell recovery in HIV-1 infected children and adolescents. Pediatric AIDS Clinical Trials Group. Lancet 2003; 362:2045-51.
5. Puthanakit T, Oberdorfer A, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodefiency virus-infected Thai children. Pediatr Infect Dis J 2006; 25:53-8.
6. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, Health Resources and Services Administration, National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric infection. Available at: http://aidsinfo.nih.gov/Guidelines/ GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID= 8&ClassID=1. Accessed 27 November 2006.
7. El-Sadr W, for the SMART Study Group. Inferior clinical outcomes with episodic CD4-guided antiretroviral therapy aimed at drug conservation (DC) in the SMART Study: consistency of findings in all patient subgroups [abstract WEAB0204]. In: Program and abstracts of the XVI International AIDS Conference (Toronto). Geneva: International AIDS Society, 2006.